<SEC-DOCUMENT>0001193125-25-157390.txt : 20250710
<SEC-HEADER>0001193125-25-157390.hdr.sgml : 20250710
<ACCEPTANCE-DATETIME>20250710080017
ACCESSION NUMBER:		0001193125-25-157390
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250707
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250710
DATE AS OF CHANGE:		20250710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cogent Biosciences, Inc.
		CENTRAL INDEX KEY:			0001622229
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				465308248
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38443
		FILM NUMBER:		251114855

	BUSINESS ADDRESS:	
		STREET 1:		275 WYMAN STREET
		STREET 2:		3RD FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-945-5576

	MAIL ADDRESS:	
		STREET 1:		275 WYMAN STREET
		STREET 2:		3RD FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Unum Therapeutics Inc.
		DATE OF NAME CHANGE:	20180402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Unum Therapeutics, Inc.
		DATE OF NAME CHANGE:	20141014
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d92808d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cogt="http://www.cogentbio.com/20250707" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-307">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-07-07_to_2025-07-07">0001622229</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="cogt-20250707.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-07-07_to_2025-07-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001622229</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-07-07</xbrli:startDate> <xbrli:endDate>2025-07-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-318">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt:datemonthdayyearen" id="ixv-319">July&#160;7, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-320">COGENT BIOSCIENCES, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:stateprovnameen" id="ixv-321">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-322">001-38443</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-323">46-5308248</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-324">275 Wyman Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-325">3rd Floor</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-326">Waltham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:stateprovnameen" id="ixv-327">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-328">02451</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-329">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-330">945-5576</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check&#160;the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:boolballotbox" id="ixv-331">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:boolballotbox" id="ixv-332">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:boolballotbox" id="ixv-333">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:boolballotbox" id="ixv-334">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act: &#8195;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-335">Common stock, $0.001 Par Value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-336">COGT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:exchnameen" id="ixv-337">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934.</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-07-07_to_2025-07-07" format="ixt-sec:boolballotbox" id="ixv-338">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;8, 2025, Cogent Biosciences, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (&#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, Leerink Partners LLC and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the &#8220;Underwriters&#8221;), to issue and sell 22,222,223 shares of the Company&#8217;s common stock at a public offering price of $9.00 per share (the &#8220;Offering&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company granted the Underwriters a <span style="white-space:nowrap">30-day</span> option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions (the &#8220;Option&#8221;), and such Option has been exercised in full by the Underwriters. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gross proceeds from the Offering, including proceeds from the exercise in full of the Option by the Underwriters, are expected to be approximately $230&#160;million before deducting customary underwriting discounts and offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are offered pursuant to an automatic shelf registration statement on Form&#160;S-3ASR (File <span style="white-space:nowrap">No.&#160;333-269707)</span> filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on February&#160;10, 2023, which became automatically effective upon filing. A final prospectus supplement, dated July&#160;8, 2025, relating to and describing the terms of the Offering was filed with the SEC on July&#160;9, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute payments that the Underwriters may be required to make because of such liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement is filed as Exhibit&#160;1.1 and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Gibson, Dunn&#160;&amp; Crutcher LLP relating to the validity of the issuance and sale of the shares of common stock in the Offering is filed herewith as Exhibit 5.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2025, the Company issued a press release announcing its cash and cash equivalents and short-term marketable securities were, in the aggregate, approximately $237&#160;million as of June&#160;30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This amount represents only preliminary financial results and is based on information available to management as of July&#160;7, 2025. The Company&#8217;s actual financial results as of, and for the six months ended, June&#160;30, 2025 are subject to the completion of its financial statements as of such date and for such period. The Company&#8217;s actual financial results as of, and for the six months ended, June&#160;30, 2025 may differ from the preliminary financial results it has provided as a result of completion of its final adjustments, review by our independent registered public accountants and other developments arising between now and the time that our financial results for such period are finalized, although the Company does not expect the actual results to differ materially from its preliminary estimate. The preliminary financial information provided has been prepared by, and is the responsibility of, the Company&#8217;s management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial information. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. Complete results as of, and for the six months ended, June&#160;30, 2025 will be included in the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the six months ended June&#160;30, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d92808dex11.htm">Underwriting Agreement, dated as of July&#160;8, 2025, by and between the Company and J.P. Morgan Securities LLC, Leerink Partners LLC and Guggenheim Securities, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d92808dex51.htm">Opinion of Gibson, Dunn&#160;&amp; Crutcher LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d92808dex51.htm">Consent of Gibson, Dunn&#160;&amp; Crutcher LLP (included in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d92808dex991.htm">Press release issued by Cogent Biosciences, Inc. on July&#160;7, 2025, furnished herewith </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> formatted in Inline XBRL</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: July&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">COGENT BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Evan Kearns</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Evan Kearns</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Legal Officer and Corporate Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d92808dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COGENT BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>22,222,223 Shares of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July&nbsp;8, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEERINK PARTNERS LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GUGGENHEIM SECURITIES, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Guggenheim Securities, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">330 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cogent Biosciences, Inc.,
a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in <U>Schedule I</U> hereto (the &#147;<B>Underwriters</B>&#148;), for whom J.P. Morgan Securities LLC, Leerink Partners LLC and
Guggenheim Securities, LLC are acting as representatives (the &#147;<B>Representatives</B>&#148;), 22,222,223 shares of its common stock, par value $0.001 per share (the &#147;<B>Firm Shares</B>&#148;). The Company also proposes to issue and sell to
the Underwriters not more than an additional 3,333,333 shares of its common stock, par value $0.001 per share (the &#147;<B>Additional Shares</B>&#148;), if and to the extent that the Representatives shall have determined to exercise, on behalf of
the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section&nbsp;2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &#147;<B>Shares</B>.&#148; The shares
of common stock, par value $0.001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#147;<B>Common Stock</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) an automatic shelf registration
statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269707),</FONT> including a prospectus, relating to certain securities of the Company (the &#147;<B>Shelf Securities</B>&#148;),
including the Shares, to be issued from time to time by the Company. The registration statement as amended at the time of effectiveness, including the information, if any, deemed to be part of the registration statement pursuant to Rule 430A or Rule
430B under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), is hereinafter referred to as the &#147;<B>Registration Statement</B>,&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the related preliminary prospectus covering the Shelf Securities is hereinafter referred to as the &#147;<B>Basic</B> <B>Prospectus</B>.&#148; The Basic Prospectus, as supplemented by the
prospectus supplement specifically related to the Shares in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the
Securities Act) is hereinafter referred to as the &#147;<B>Prospectus</B>,&#148; and the term &#147;<B>preliminary prospectus</B>&#148; means any preliminary form of the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act,
&#147;<B>Time of Sale Prospectus</B>&#148; means the preliminary prospectus together with the documents and pricing information set forth in <U>Schedule II</U> hereto, and &#147;<B>broadly available road show</B>&#148; means a &#147;bona fide
electronic road show&#148; as defined in Rule 433(h)(5) under the Securities Act that has been made available without restriction to any person. As used herein, the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148;
&#147;Time of Sale Prospectus&#148; and &#147;Prospectus&#148; shall include the documents, if any, incorporated by reference therein as of the date hereof. The terms &#147;<B>supplement</B>,&#148; &#147;<B>amendment</B>&#148; and
&#147;<B>amend</B>&#148; as used herein with respect to the Registration Statement, the Prospectus, the Time of Sale Prospectus or the Prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the
Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), that are deemed to be incorporated by reference therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
<I>Representations and Warranties</I>. The Company represents and warrants to and agrees with each of the Underwriters that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The
Registration Statement is an &#147;automatic shelf registration statement&#148; (as defined in Rule 405 under the Securities Act) and became automatically effective upon filing thereof; no stop order suspending the effectiveness of the Registration
Statement is in effect, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission pursuant to Section&nbsp;8A of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus
or the Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii)&nbsp;the Registration Statement, when it became effective, did not
contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
(iii)&nbsp;the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder,
(iv)&nbsp;the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;4), the
Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, (v)&nbsp;each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misleading and (vi)&nbsp;the Prospectus does not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the
Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being
understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;8(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company is not an &#147;ineligible issuer&#148; in connection with the offering pursuant to Rules 164, 405 and 433 under the
Securities Act, and the Company is a well-known seasoned issuer, as defined in Rule 405 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be,
filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to
Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations
of the Commission thereunder. Except for the free writing prospectuses, if any, identified in <U>Schedule II</U> hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company has not prepared, used or
referred to, and will not, without the prior consent of the Representatives, prepare, use or refer to, any free writing prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described
in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent
that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each subsidiary of the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each
jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole. All of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT>
and are owned directly by the Company, free and clear of all liens, encumbrances, equities or claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) This Agreement has been duly
authorized, executed and delivered by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The authorized capital stock of the Company (including the Shares) conforms as to legal
matters to the description thereof contained in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
The shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable,</FONT> and the issuance of such Shares will not be subject to any preemptive or similar rights that have not been validly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Neither the execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement, nor the
issuance and sale of the Shares, will contravene any provision of applicable law or the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company or conflict with, result in a breach or violation of any of the
terms or provisions of, constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its
subsidiaries pursuant to any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument, in each case, that is material to the Company and its subsidiaries, take as a whole, to which the Company or any of its subsidiaries is
a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, or any judgment, order or decree of any governmental body, agency or court having
jurisdiction over the Company or any subsidiary; and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under this Agreement,
except such as have already been obtained or made or as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) With respect to the stock options (the &#147;<B>Stock Options</B>&#148;) granted pursuant to the stock-based compensation plans of the
Company and its subsidiaries (the &#147;<B>Company Stock Plans</B>&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the
&#147;<B>Code</B>&#148;) so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as
applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such
grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements,
including the rules of the Nasdaq Global Select Market and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with U.S. generally accepted accounting principles
(&#147;<B>GAAP</B>&#148;) in the financial statements (including the related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws, except where the
failure to make such grants in accordance with the foregoing clauses (i)&nbsp;through (iv) would not, singly or in the aggregate, have a material adverse effect on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company and its subsidiaries, taken as a whole. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to,
or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its subsidiaries or their results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT>
or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in
any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property or asset of the
Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses
(ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) There has not occurred any material adverse change, or any development that, singly or in the aggregate, would reasonably be expected to
result in a material adverse change in the condition, financial or otherwise, or in the earnings, business, management, prospects or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale
Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) There are no legal or governmental proceedings pending or, to the Company&#146;s knowledge, threatened to which the
Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in the Time of Sale Prospectus and
proceedings that, singly or in the aggregate, would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate
the transactions contemplated by the Time of Sale Prospectus or (ii)&nbsp;that are required to be described in the Registration Statement or the Prospectus and are not so described. There are no statutes, regulations, contracts or other documents
that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that are not described or filed as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Each preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed
pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company is not, and after giving effect to the offering and sale of the Shares, and the application of the proceeds thereof as
described in the Prospectus will not be, required to register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) The Company and its subsidiaries (i)&nbsp;are in compliance with any and all applicable
foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;), (ii) have
received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval,
except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the
aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) There are no costs or liabilities
associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit,
license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) There are no contracts, agreements or understandings between the Company and any person granting such person the right to require the
Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement, except those
contracts, agreements or understandings described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, all of which have been validly waived in connection with the issuance and sale of the Shares contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) None of the Company, its subsidiaries or their respective affiliates, or any director, officer or employee thereof, or, to the
Company&#146;s knowledge, any agent or representative of the Company, its subsidiaries or their respective affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay or authorization or approval of the payment,
giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) in order to influence official action, or to any person in violation of
any applicable anti-corruption laws; and the Company, its subsidiaries and their respective affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to
maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein. Neither the Company nor its subsidiaries will use, directly or indirectly, the
proceeds of the offering in furtherance of an offer, payment, promise to pay or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) The operations of the Company and its subsidiaries are and have been conducted at all
times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or
similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) (i) None of the Company, any of its subsidiaries, or any director, officer or employee thereof, or, to the Company&#146;s knowledge, any
agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&#147;<B>Person</B>&#148;) that is, or is owned or controlled by one or more Persons that are: (A)&nbsp;the subject of any sanctions
administered or enforced by the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, His Majesty&#146;s Treasury or other relevant sanctions authority (collectively,
&#147;<B>Sanctions</B>&#148;), or (B)&nbsp;located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s
Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, the Crimea Region of Ukraine, the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Zaporizhzhia and Kherson Regions, Cuba,
Iran, North Korea and Syria). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company will not, directly or indirectly, use the proceeds of the offering, or
lend, contribute or otherwise make available such proceeds to any direct or indirect subsidiary, joint venture partner or other Person: (A)&nbsp;to fund or facilitate any activities or business of or with any Person or in any country or territory
that, at the time of such funding or facilitation, is the subject of Sanctions; or (B)&nbsp;in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter,
advisor, investor or otherwise). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company and its subsidiaries have not knowingly engaged in, are not now
knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Subsequent to the respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and
the Prospectus, (i)&nbsp;the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (ii)&nbsp;the Company has not purchased any of its outstanding capital
stock (except in connection with the departure of an employee or consultant and pursuant to the terms of an existing agreement between such person and the Company of which the Underwriters have been advised in writing), nor declared, paid or
otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends and (iii)&nbsp;there has not been any material change in the capital stock, short-term debt or long-term debt of the Company and
its subsidiaries, except in each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) The Company does not own any real property. The Company and its subsidiaries have good
and marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale
Prospectus or such as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries. Any real property and buildings held under
lease by the Company or its subsidiaries are held by the Company or any of its subsidiaries, as applicable, under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and
proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as described in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) The Company and its subsidiaries own or have valid, binding and enforceable licenses under all patents, patent applications, patent
rights, licenses, inventions, copyrights, <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks,
trade names and other intellectual property used in or necessary for the conduct of the business of the Company and its subsidiaries in the manner described in the Time of Sale Prospectus (collectively, the &#147;<B>Intellectual Property</B>&#148;),
except as enforceability of any licenses may be limited by bankruptcy and other similar laws affecting the rights of creditors generally and general principles of equity. The patents, trademarks and copyrights, if any, included within the
Intellectual Property are valid, enforceable and subsisting, other than as disclosed in the Time of Sale Prospectus. (i)&nbsp;Neither the Company nor any of its subsidiaries is obligated to pay a material royalty, grant a license to or provide other
material consideration to any third party in connection with the Intellectual Property, except as described in the Time of Sale Prospectus; (ii)&nbsp;neither the Company nor any of its subsidiaries has received any notice of any claim of
infringement, misappropriation of or conflict with asserted rights of others with respect to any of the Company&#146;s or the subsidiaries&#146; product candidates, processes or Intellectual Property; (iii)&nbsp;no action, suit, claim or other
proceeding is pending or, to the knowledge of the Company, is threatened, challenging the Company&#146;s or any subsidiary&#146;s rights in or to any Intellectual Property or challenging the validity, enforceability or scope of any Intellectual
Property; (iv)&nbsp;none of the development, manufacture, sale or use of any of the discoveries, inventions, product candidates or processes of the Company referred to in the Time of Sale Prospectus do or will infringe or violate any right or issued
patent claim of any third party in any material respect; (v)&nbsp;no third party has any ownership right in or to any Intellectual Property that is owned by the Company other than any <FONT STYLE="white-space:nowrap">co-owner</FONT> of any patent
constituting Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office and any <FONT STYLE="white-space:nowrap">co-owner</FONT> of any patent application constituting Intellectual Property who is named in such patent
application; (vi)&nbsp;except as would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, the Intellectual Property owned by the Company or its subsidiaries is free and clear of all
liens or encumbrances, except as described in the Time of Sale Prospectus; (vii)&nbsp;none of the technology employed by the Company or its subsidiaries in the conduct of the business in the manner described in the Time of Sale Prospectus has been
obtained or is being used by the Company or its subsidiaries in material violation of any contractual obligation binding on the Company or, to the knowledge of the Company, upon any of its officers, consultants, directors or employees and
(viii)&nbsp;the Company has taken reasonable measures to protect its confidential information and trade secrets and to maintain and safeguard the Intellectual Property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) All patent and patent applications owned by or licensed to the Company or its
subsidiaries have been duly and properly filed, prosecuted and maintained in all material respects; to the knowledge of the Company, the parties prosecuting the patent applications owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> by the
Company and patent applications from which patents owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> by the Company have issued have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office in connection with
such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or would reasonably be
expected to form the basis of a finding of invalidity with respect to any patents that have been issued with respect to such applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) The Company and its subsidiaries have operated and currently are in compliance in all material respects with all applicable laws, rules
and regulations of the jurisdictions in which they are conducting business. Each of the Company and its subsidiaries (i)&nbsp;is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership,
testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product candidate under development, manufactured or distributed by the
Company (&#147;<B>Applicable Laws</B>&#148;); (ii) in the past five years has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or notice from the U.S. Food and Drug
Administration (the &#147;<B>FDA</B>&#148;) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals,
clearances, authorizations, permits and supplements or amendments thereto required by any Applicable Laws to conduct the Company&#146;s business as described in Time of Sale Prospectus (&#147;<B>Authorizations</B>&#148;); (iii) possesses all
material Authorizations and such Authorizations are valid and in full force and effect and neither the Company nor any of its subsidiaries is in material violation of any such Authorizations; (iv)&nbsp;has not received notice of any pending or
completed claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product
candidate operation or activity is in material violation of any Applicable Laws or Authorizations and the Company has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is
considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v)&nbsp;in the past five years has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority
has taken, is taking or intends to take action to limit, suspend, materially modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is
considering such action; (vi)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or
Authorizations and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent
submission) and (vii)&nbsp;has not, either voluntarily or involuntarily, initiated, conducted or issued or caused to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initiated, conducted or issued, any recall, safety alert, &#147;dear doctor&#148; letter or other notice or action relating to the alleged lack of safety or efficacy of any product candidate or
any alleged product candidate defect or violation and, to the Company&#146;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) The preclinical studies, tests and clinical trials conducted by the Company that are described in the Registration Statement, the Time of
Sale Prospectus and the Prospectus, and, to the Company&#146;s knowledge, those preclinical studies, tests and clinical trials conducted on behalf of the Company, were and, if still pending, are being conducted in all material respects in accordance
with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug, and Cosmetic Act and the rules and
regulations promulgated thereunder. The descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus are accurate and complete and fairly present the data
derived from such studies, tests and trials in all material respects. The Company is not aware of any studies, tests or trials, the results of which the Company believes are materially inconsistent with the study, test or trial results described or
referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus when viewed in the context in which such results are described and the clinical state of development. The Company has not received any notices or written
correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority requiring the termination, suspension or material modification of, or prohibiting the commencement of, any preclinical studies, tests or
clinical trials conducted by or on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) None of the Company, any of its officers, directors or managing employees
(as defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-5(b))</FONT> or, to the knowledge of the Company, agents, is or has been excluded, suspended or debarred from participation in any state or federal health care program, or made
subject to any pending or, to the Company&#146;s knowledge, threatened or contemplated action which could reasonably be expected to result in such exclusion, suspension or debarment. The Company is not a party to or has any ongoing reporting
obligations pursuant to any corporate integrity agreement, deferred or <FONT STYLE="white-space:nowrap">non-prosecution</FONT> agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any
governmental authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) To the knowledge of the Company, the manufacturing facilities and operations of its suppliers are operated
in compliance in all material respects with all Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) None of the Company&#146;s or the subsidiaries&#146; product
candidates have received marketing approval from the FDA or any other federal, state, local or foreign governmental or regulatory authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) No material labor dispute with the employees of the Company or any of its subsidiaries exists, except as described in the Time of Sale
Prospectus, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that would,
individually or in the aggregate, have or be reasonably likely to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) Except (i)&nbsp;as described in the Time of Sale Prospectus or (ii)&nbsp;as would not,
singly or in the aggregate, have, or reasonably be expected to have, a material adverse effect on the Company and its subsidiaries, taken as a whole, each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee Retirement
Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), that the Company or any member of its &#147;Controlled Group&#148; (defined as any organization which is under common control with the Company within the meaning of Section&nbsp;414
of the Code) sponsors or maintains has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) The Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary for similarly sized companies in the business in which they are engaged. Neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for. Neither the Company nor any
of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a
cost that would not, individually or in the aggregate, have or reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) The Company and its subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or
permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have or reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described
in the Time of Sale Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) PricewaterhouseCoopers LLP, which has certified certain financial statements of the Company and its
subsidiaries, is an independent public accountant as required by the Securities Act and the rules and regulations of the Commission thereunder and the rules and regulations of the Public Company Accounting Oversight Board (United States). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) The consolidated financial statements of the Company included or incorporated by reference in the Registration Statement, the Time of
Sale Prospectus and the Prospectus, together with the related notes, present fairly in all material respects the financial position of the Company and its consolidated subsidiaries at the dates indicated and, in the case of the statements of
operations, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries, for the periods specified. The consolidated financial statements of the Company included or incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and have been prepared in conformity with GAAP applied on a consistent basis throughout the periods
involved except (i)&nbsp;the unaudited, interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the
Commission and (ii)&nbsp;as otherwise disclosed therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the
Time of Sale Prospectus or the Prospectus under the Securities Act and the rules and regulations of the Commission thereunder. All other information regarding the financial condition or results of operations of the Company or its subsidiaries
included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material
respects the information shown thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) The Company and each of its subsidiaries maintains a system of internal accounting controls
sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement is accurate. Except as described in the Time of Sale Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (i)&nbsp;no material weakness in the
Company&#146;s internal control over financial reporting (whether or not remediated) and (ii)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) The Company maintains disclosure controls and procedures (as such term
is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) that are designed to comply with the requirements of the Exchange Act. Such disclosure controls and procedures have been designed to ensure that material
information relating to the Company is made known to the Company&#146;s principal executive officer and principal financial officer by others within the Company; and such disclosure controls and procedures are effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Except as described in the Time of Sale Prospectus, the Company has not sold, issued or distributed any shares of Common Stock during the
<FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified
stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) Neither the Company
nor any of its subsidiaries has any securities rated by any &#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) The Company and each of its subsidiaries has filed all federal, state, local and foreign tax returns required to be filed through the
date of this Agreement or has requested extensions thereof (except where the failure to file would not, individually or in the aggregate, have a material adverse effect) and has paid all taxes required to be paid thereon (except for cases in which
the failure to file or pay would not have a material adverse effect, or, except as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the Company), and no tax deficiency has been determined adversely
to the Company or any of its subsidiaries which has had (nor does the Company nor its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its subsidiaries
and which could reasonably be expected to have) a material adverse effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) The Shares are registered pursuant to Section&nbsp;12(b)
or 12(g) of the Exchange Act and are listed on the Nasdaq Global Select Market (the &#147;<B>Exchange</B>&#148;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the
Exchange Act or delisting the Shares from the Exchange, nor has the Company received any notification that the Commission or the Exchange is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance
with all applicable listing requirements of the Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) Other than its subsidiaries, the Company, directly or indirectly, owns no
capital stock or other equity or ownership or proprietary interest in any corporation, partnership, association, trust or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) [Reserved.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) The
Company (i)&nbsp;has not engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication and (ii)&nbsp;has not authorized anyone to engage in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. &#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means any oral or written communication
with potential investors undertaken in reliance on Section&nbsp;5(d) of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) As of the time of each sale of the
Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers, none of (i)&nbsp;the Time of Sale Prospectus and (ii)&nbsp;any free writing prospectus, when considered together with the Time of Sale
Prospectus, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or
that might cause or result in stabilization or manipulation of the price of the Shares or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (&#147;<B>Regulation M</B>&#148;)) with respect to the
Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person
required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been described as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) [Reserved.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) All statistical, demographic and market related data included in the Registration
Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects. To the extent required, the Company has obtained
the written consent to the use of such data from such sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) There is, and has been, no failure on the part of the Company or any
of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith, including
Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) [Reserved.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) Each financial or operational projection or other &#147;forward-looking statement&#148; (as defined by Section&nbsp;27A of the
Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with reasonable basis after due consideration by
the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from
those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) [Reserved.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) The
Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and
perform, in each case, in all material respects, as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time
bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their
material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means
(i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit
card number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as
defined by GDPR; (iv)&nbsp;any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and
Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an
identified person&#146;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or
investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory
authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal
data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are
in compliance with, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have
in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and
analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures
made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any
subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to
result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that
imposes any obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several
Underwriters, and each Underwriter, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective numbers of
Firm Shares set forth in <U>Schedule I</U> hereto opposite its name at a price per Firm Share of $8.46 (the &#147;<B>Purchase Price</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to
sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly, up to 3,333,333 Additional Shares at the Purchase Price (the &#147;<B>Option</B>&#148;), provided, however, that the
amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not payable on such Additional Shares. The Representatives may
exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice not later than 30 days after the date of this Agreement (the &#147;<B>Option Period</B>&#148;). Any exercise notice shall specify the
number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business day after the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written notice is given and may not be earlier than the closing date for the Firm Shares nor later than ten business days after the date of such notice. On each day, if any, that Additional
Shares are to be purchased (an &#147;<B>Option Closing Date</B>&#148;), each Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as the
Representatives may determine) that bears the same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set forth in <U>Schedule I</U> hereto opposite the name of such
Underwriter bears to the total number of Firm Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Terms of Public Offering</I>. The Company is advised by the Representatives that the
Underwriters propose to make a public offering of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in the Representatives&#146; judgment is advisable. The Company is further
advised by the Representatives that the Shares are to be offered to the public initially at a price per Firm Share of $9.00 (the &#147;<B>Public Offering Price</B>&#148;) and to certain dealers selected by the Representatives at a price that
represents a concession not in excess of $0.324 per Firm Share under the Public Offering Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Payment and Delivery. </I>Payment for the Firm
Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on July 10, 2025, or
at such other time on the same or such other date, not later than July 24, 2025, as shall be designated in writing by the Representatives. The time and date of such payment are hereinafter referred to as the &#147;<B>Closing Date</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against
delivery of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section&nbsp;2 or at such other time on the same or on such
other date, in any event not later than August&nbsp;8, 2025, as shall be designated in writing by the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares shall
be registered in such names and in such denominations as the Representatives shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Shares shall be
delivered to the Representatives on the Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with transfer taxes payable in connection with the transfer of the Shares to the
Underwriters, if any, duly paid, against payment of the Purchase Price therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Conditions to the Underwriters&#146; Obligations</I>. The
obligations of the Company to sell the Shares to the Underwriters and the several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the accuracy of the representations and warranties set forth in
this Agreement as of the date hereof and as of the Closing Date, as well as the condition that the Registration Statement has become effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The several obligations of the Underwriters are subject to the following further conditions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant
to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each issuer free writing prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an
issuer free writing prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the
reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subsequent to the execution and delivery of this Agreement and prior to the Closing
Date there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business, prospects or operations of the Company and its subsidiaries, taken as a whole,
from that set forth in the Time of Sale Prospectus that, in the Representatives&#146; judgment, is material and adverse and that makes it, in the Representatives&#146; judgment, impracticable to market the Shares on the terms and in the manner
contemplated in the Time of Sale Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Underwriters shall have received on the Closing Date a certificate, dated the
Closing Date and signed by an executive officer of the Company, to the effect set forth in Section&nbsp;5(b) above and to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the
Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. The officer signing and delivering such certificate may
rely upon the best of his or her knowledge as to proceedings threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Underwriters shall have received on the Closing Date an
opinion and negative assurance letter of Gibson, Dunn&nbsp;&amp; Crutcher LLP, outside counsel for the Company, dated the Closing Date, covering tax disclosure and other customary matters in form and substance reasonably satisfactory to the
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Underwriters shall have received on the Closing Date an opinion of Goodwin Procter LLP, special counsel to the
Company with respect to certain intellectual property matters, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C., counsel for the Underwriters, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to certain provisions included in the opinions to be delivered pursuant to Sections 5(d) and 5(f) above, Gibson, Dunn&nbsp;&amp;
Crutcher LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. may state that their opinions and beliefs are based upon their participation in the preparation of the Registration Statement, the Time of Sale Prospectus and the Prospectus and
any amendments or supplements thereto (other than the documents incorporated by reference) and upon review and discussion of the contents thereof (including documents incorporated by reference), but are without independent check or verification,
except as specified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions of Gibson, Dunn&nbsp;&amp; Crutcher LLP and Goodwin Procter LLP described in
Sections 5(d) and 5(e) above shall be rendered to the Underwriters at the request of the Company and shall so state therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The
Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Underwriters, from PricewaterhouseCoopers LLP,
independent public accountants, containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information
contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than the
date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, each substantially in the form of <U>Exhibit A</U>
hereto, among the Representatives and certain shareholders, officers, directors and director-affiliated funds of the Company relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to the
Representatives on or before the date hereof (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</B>&#148;), shall be in full force and effect on the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Underwriters shall have received, on each of the date hereof and the Closing Date, a certificate of the chief financial officer of the
Company certifying as to the accuracy of certain financial information included in the Registration Statement, the Time of Sale Prospectus and the Prospectus, in form and substance satisfactory to the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the accuracy of the representations and
warranties set forth in this Agreement as of applicable Option Closing Date, as well as the delivery to the Underwriters on the applicable Option Closing Date of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the
certificate delivered on the Closing Date pursuant to Section&nbsp;5(c) hereof remains true and correct as of such Option Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an opinion and negative assurance letter of Gibson, Dunn&nbsp;&amp; Crutcher LLP, outside counsel for the Company, dated
the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(d) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an opinion of Goodwin Procter LLP, special counsel to the Company with respect to certain intellectual property matters,
dated the Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(e) hereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
an opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise
to the same effect as the opinion required by Section&nbsp;5(f) hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) a letter dated the Option Closing Date, in form and substance
satisfactory to the Underwriters, from PricewaterhouseCoopers LLP, independent public accountants, substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section&nbsp;5(g) hereof; <I>provided</I> that
the letter delivered on the Option Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than two business days prior to such Option Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) a certificate, dated the Option Closing Date, certifying as to the accuracy of certain financial information included in
the Registration Statement and the Prospectus, in form and substance satisfactory to the Underwriters; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) such
other documents as the Representatives may reasonably request with respect to the good standing of the Company, the due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the
issuance of such Additional Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To furnish to the Representatives, without charge, three conformed copies of the Registration Statement (including exhibits thereto and
documents incorporated by reference) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto but including documents incorporated by reference) and to furnish to the Representatives in New
York City, without charge, prior to 10:00 a.m. New York City time on the second business day succeeding the date of this Agreement and during the period mentioned in Section&nbsp;6(e) or 6(f) below, as many copies of the Time of Sale Prospectus, the
Prospectus, any documents incorporated by reference therein and any supplements and amendments thereto or to the Registration Statement as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to the
Representatives a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the Representatives reasonably object, and to file with the Commission within the applicable period specified in
Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To furnish to the Representatives a
copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which the Representatives reasonably object. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Not to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule
433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a
time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in
the light of the circumstances, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file, or if, in the
opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any
dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is
delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will
comply with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) If, during such period after the first date of the public offering of the Shares as in the opinion of
counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the
Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the Commission
and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses the Representatives will furnish to the Company) to which Shares may have been sold by the Representatives on behalf of the Underwriters and to any
other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice
referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) To file the Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A or 430B under the Securities
Act, to file any issuer free writing prospectus to the extent required by Rule 433 under the Securities Act; and to file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission
pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Shares; and to furnish copies
of the Prospectus and each issuer free writing prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such
quantities as the Representatives may reasonably request.&nbsp;The Company also agrees to pay the registration fee for this offering within the time period required by Rule 456(b)(1) under the Securities Act (without giving effect to the proviso
therein) and in any event prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) To advise the Representatives promptly, and confirm such advice in writing,
(i)&nbsp;when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Time of Sale Prospectus, the Prospectus or any
issuer free writing prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the
receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of
any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or the initiation or threatening of any proceeding for that purpose
or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development as a result of which the Prospectus, Time of Sale Prospectus, or issuer free writing prospectus, as then amended or supplemented would
include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Time of Sale Prospectus, or any such issuer free
writing prospectus is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to
Rule 401(g)(2) under the Securities Act; and to use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any preliminary prospectus or
the Time of Sale Prospectus or the Prospectus or suspending any such qualification of the Shares and, if any such order is issued, to obtain as soon as possible the withdrawal thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives
shall reasonably request; provided that, in connection therewith, the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction or subject itself to taxation in any such
jurisdiction if it is not otherwise so subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) To make generally available to the Company&#146;s security holders and to the
Representatives as soon as practicable an earnings statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of
Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Whether or not the transactions
contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses of
the Company&#146;s counsel and the Company&#146;s accountants in connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration
Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all
printing costs associated therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified; (ii)&nbsp;all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including transfer or other taxes, if any, payable thereon; (iii)&nbsp;the cost of printing or producing
any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as
provided in Section&nbsp;6(i) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum;
(iv)&nbsp;all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering of the Shares by the Financial Industry Regulatory Authority (provided, that,
the amount payable by the Company with respect to fees and disbursements of counsel for the Underwriters pursuant to subsections (iii)&nbsp;and (iv) shall not exceed $30,000); (v) all costs and expenses incident to listing the Shares on the
Exchange; (vi)&nbsp;the cost of printing certificates representing the Shares; (vii)&nbsp;the costs and charges of any transfer agent, registrar or depositary; (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on
any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the
production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the
Company and any such consultants, and one half of the cost of any aircraft chartered in connection with the road show (provided that no aircraft shall be chartered without the consent of the Company and provided further that, for the avoidance of
doubt, the Underwriters shall pay their own travel expenses, including lodging, transportation, meals and entertainment, other than the portion of the cost of the aircraft set forth above); (ix) the document production charges and expenses
associated with printing this Agreement; and (x)&nbsp;all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however, that
except as provided in this Section, Section&nbsp;8 entitled &#147;Indemnity and Contribution&#148; and the last paragraph of Section&nbsp;11 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their
counsel, stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any offers they may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) [Reserved.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) The
Company will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying
documentation, and the Company undertakes to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification of the foregoing Certification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) [Reserved.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company also covenants with each Underwriter that, without the prior written consent
of the Representatives on behalf of the Underwriters, it will not, during the period ending 60 days after the date of the Prospectus (the &#147;<B>Restricted Period</B>&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause
(1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3)&nbsp;file any registration statement with the Commission relating to the offering of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock or publicly disclose the intention to do any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
restrictions contained in the preceding paragraph shall not apply to (a)&nbsp;the Shares to be sold hereunder, (b)&nbsp;the issuance by the Company of shares of Common Stock upon the exercise of an option or warrant or the conversion of a security
outstanding on the date hereof pursuant to stock plans disclosed in the Time of Sale Prospectus, (c)&nbsp;the filing by the Company of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto in
respect of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock issued under or the grant of any award pursuant to stock plans disclosed in the Time of Sale Prospectus, (d)&nbsp;sales of
shares of Common Stock pursuant to the Sales Agreement, dated May&nbsp;6, 2022, by and between the Company and Guggenheim Securities, LLC or any replacement &#147;at the market offering&#148; program; provided that in the case of clause (d), no such
sales may be made prior to the expiration of the Option Period unless the Option has been exercised in full and all Additional Shares have been issued; (e)&nbsp;the entry into an agreement providing for the issuance by the Company of shares of
Common Stock or any security convertible into or exercisable for Common Stock in connection with the acquisition by the Company or its subsidiaries of the securities, business, property or other assets of another person or entity or pursuant to an
employee benefit plan assumed by the Company in connection with such acquisition, and the issuance of any such securities pursuant to any such agreement, or (f)&nbsp;the entry into an agreement providing for the issuance of shares of Common Stock or
any security convertible into or exercisable for shares of Common Stock in connection with joint ventures, commercial relationships or other strategic transactions, and the issuance of any such securities pursuant to any such agreement; provided
that in the case of clauses (e)&nbsp;and (f), the aggregate number of shares of Common Stock or any security convertible into or exercisable for Common Stock (on an <FONT STYLE="white-space:nowrap">as-converted,</FONT>
<FONT STYLE="white-space:nowrap">as-exercised</FONT> or <FONT STYLE="white-space:nowrap">as-exchanged</FONT> basis) that the Company may sell or issue or agree to sell or issue pursuant to clauses (e)&nbsp;and (f) shall not exceed 5% of the total
number of shares of Common Stock issued and outstanding immediately following the completion of the transactions contemplated by this agreement, including the issuance and sale of Shares and all recipients of shares of Common Stock or any security
convertible into or exercisable for Common Stock shall enter into a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement with respect to the remaining portion of the Restricted Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Covenants of the Underwriters</I>. Each Underwriter severally covenants with the Company not to take any action that would result in the Company being
required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Indemnity and Contribution</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning
of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate, director and officer of any Underwriter within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims,
damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or based upon any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule
433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, any road show as defined in Rule 433(h) under the Securities Act (a &#147;<B>road
show</B>&#148;), the Prospectus or any amendment or supplement thereto, caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except
insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in subsection (b)&nbsp;below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the
Registration Statement and each person, if any, who controls the Company within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such
Underwriter, but only with reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, any preliminary prospectus, the
Time of Sale Prospectus, any issuer free writing prospectus, road show or the Prospectus or any amendment or supplement thereto, it being understood and agreed upon that the only such information furnished by any Underwriter consists of the
following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the third paragraph under the caption &#147;Underwriting,&#148; and the information contained under the caption
&#147;Underwriting&#151;Stabilization.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In case any proceeding (including any governmental investigation) shall be instituted
involving any person in respect of which indemnity may be sought pursuant to Section&nbsp;8(a) or 8(b), such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such indemnity may be sought (the
&#147;<B>indemnifying party</B>&#148;) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the
indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and
expenses of such counsel shall be at the expense of such indemnified party unless (i)&nbsp;the indemnifying party and the indemnified party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall have mutually agreed to the retention of such counsel, (ii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the
indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them, or (iii)&nbsp;the indemnifying party has failed within a reasonable period of time to
appoint counsel reasonably satisfactory to the indemnified party. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be
designated in writing by the Representatives, in the case of parties indemnified pursuant to Section&nbsp;8(a), and by the Company, in the case of parties indemnified pursuant to Section&nbsp;8(b). The indemnifying party shall not be liable for any
settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or
liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than
60 days after receipt by the indemnifying party of such request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall,
without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such
indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding and does not include a statement as to or an admission of fault,
culpability or a failure to act by or on behalf of any indemnified party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) To the extent the indemnification provided for in
Section&nbsp;8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such
indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect
not only the relative benefits referred to in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses,
claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be
deemed to be in the same respective proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters, in each case
as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Price of the Shares. The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;8 are several in proportion to the respective number of Shares they have purchased hereunder,
and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this
Section&nbsp;8 were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in
Section&nbsp;8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section&nbsp;8(d) shall be deemed to include, subject to the limitations set forth above, any legal or
other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute any amount in
excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The remedies provided for in this Section&nbsp;8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The indemnity and contribution provisions contained in this Section&nbsp;8 and the representations, warranties and other statements of the
Company contained in this Agreement shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter, any person controlling any
Underwriter or any affiliate, director or officer of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Termination</I>. The Underwriters may terminate this Agreement by notice given by the Representatives to the Company, if after the execution and
delivery of this Agreement and prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE MKT, the Nasdaq Stock Market LLC, the
Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii)&nbsp;trading of any securities of the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, (iii)&nbsp;a material disruption in securities settlement, payment or clearance services in the United States shall have occurred, (iv)&nbsp;any moratorium on commercial banking
activities shall have been declared by Federal or New York State authorities or (v)&nbsp;there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or crisis that, in your judgment, is
material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in the Representatives&#146; judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the
terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Effectiveness; Defaulting Underwriters</I>. This Agreement shall become effective upon the execution
and delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the
Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is
not more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth
opposite their respective names in <U>Schedule I</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as the
Representatives may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the number of Shares that any Underwriter has agreed
to purchase pursuant to this Agreement be increased pursuant to this Section&nbsp;10 by an amount in excess of <FONT STYLE="white-space:nowrap">one-ninth</FONT> of such number of Shares without the written consent of such Underwriter. If, on the
Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the
aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate
without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company. In any such case either the Representatives or the Company shall have the right to postpone the Closing Date, but in no event for
longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any
Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate
number of Additional Shares to be purchased on such Option Closing Date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall have the option to (i)&nbsp;terminate their obligation hereunder to purchase the Additional Shares
to be sold on such Option Closing Date or (ii)&nbsp;purchase not less than the number of Additional Shares that such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters would have been obligated to purchase in the absence of such
default. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Agreement shall be terminated by the Underwriters, or any of them, pursuant to Section&nbsp;9 hereof or because of any failure or
refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the
Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including the fees and
disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Entire</I> <I>Agreement</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent not superseded by
this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the
conduct of the offering, and the purchase and sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company acknowledges that in connection with the offering of
the Shares: (i)&nbsp;the Underwriters have acted at arms length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii)&nbsp;the Underwriters owe the Company only those duties and obligations set forth in this
Agreement and prior written agreements (to the extent not superseded by this Agreement), if any, (iii)&nbsp;the Underwriters may have interests that differ from those of the Company and (iv)&nbsp;the Underwriters are not advising the Company or any
other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of
fiduciary duty in connection with the offering of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>Counterparts</I>. This Agreement may be signed in two or more counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Delivery of an executed counterpart of this Agreement by one party to the others may be made by facsimile, electronic mail
(including any electronic signature complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. &#167;&#167; <FONT STYLE="white-space:nowrap">301-309),</FONT> as amended from time to time, or other applicable law) or other
transmission method, and the parties hereto agree that any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Applicable Law</I>. This Agreement and any claim, controversy or dispute arising out of this Agreement shall be governed by and construed in accordance
with the internal laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Waiver of Jury Trial</I>. Each of the parties hereto hereby waives any right to trial by jury in
any suit or proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Consent to Jurisdiction</I>. Any legal suit, action or proceeding arising out
of or based upon this Agreement or the transactions contemplated hereby shall be instituted in (i)&nbsp;the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii)&nbsp;the courts of
the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in
regard to the enforcement of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or
document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of
venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been
brought in an inconvenient forum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <I>Headings</I>. The headings of the sections of this Agreement have been inserted for convenience of
reference only and shall not be deemed a part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <I>Persons Entitled to Benefit of Agreement</I>.&nbsp;This Agreement shall inure to
the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to herein.&nbsp;Nothing in this
Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein.&nbsp;No purchaser of Shares from any Underwriter shall be
deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. <I>Survival</I>.&nbsp;The respective indemnities, rights of contribution,
representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall
survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers,
controlling persons or affiliates referred to herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. <I>Compliance with USA Patriot Act</I>. In accordance with the requirements of the USA Patriot
Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the
Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20. <I>Notices</I>. All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed or
sent to the Representatives at c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Fascimile: (212) <FONT STYLE="white-space:nowrap">622-8358,</FONT> Attention: Equity Syndicate Desk; c/o Leerink Partners LLC, 1301 Avenue
of the Americas, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, New York 10019, attention of Stuart R. Nayman; and Guggenheim Securities, LLC, 330 Madison Avenue, New York, New York 10017, Attention: Head of Equity Capital
Markets, facsimile number: (212) <FONT STYLE="white-space:nowrap">658-9689,</FONT> with a copy (which copy shall not constitute notice) to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111,
Attention: William Hicks, Esq., John T. Rudy, Esq., and Alok A. Choksi, Esq., and if to the Company shall be delivered, mailed or sent to Cogent Biosciences, Inc., 275 Wyman Street, 3rd Floor, Waltham, MA 02451, Attn: Chief Financial Officer, with a
copy to Ryan Murr and Branden C. Berns of Gibson, Dunn&nbsp;&amp; Crutcher LLP, 555 Mission Street, San Francisco, CA 94105. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. <I>Recognition of the U.S. Special Resolution Regimes</I>. (a)&nbsp;In the event that any Underwriter
that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent
as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special
Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this
Section a &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;<B>Covered Entity</B>&#148; means any of the following:
(i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in
accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title
II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page
intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Cogent Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Green</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: John Green</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Financial Officer</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted as of the date hereof</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>J.P. Morgan Securities LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin Burdett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Benjamin Burdett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Leerink Partners LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jon Civitarese</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jon Civitarese</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Senior Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Guggenheim Securities, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shiv Taylor, MD</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Shiv Taylor, MD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Senior Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of themselves and the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters named in Schedule I hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Underwriting Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm<BR>Shares To Be<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,777,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,444,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeSci Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22,222,223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch. I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TIME OF SALE PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary prospectus dated July&nbsp;8, 2025 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Price per Share to the public: $9.00 </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Firm Shares offered: 22,222,223 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase Additional Shares: 3,333,333 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch. II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> LETTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July __, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEERINK PARTNERS LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GUGGENHEIM SECURITIES, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o LEERINK PARTNERS LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o GUGGENHEIM SECURITIES, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">330 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that J.P. Morgan Securities LLC, Leerink Partners LLC and Guggenheim Securities, LLC, as representatives (the &#147;<B>Representatives</B>&#148;) of the several underwriters (the &#147;<B>Underwriters</B>&#148;), propose to enter into an
Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Cogent Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), providing for the public offering (the &#147;<B>Public Offering</B>&#148;) by the
Underwriters, including the Representatives, of shares of the common stock, par value $0.001 per share, of the Company (the &#147;<B>Common Stock</B>&#148;). Capitalized terms used herein and not defined herein shall have the respective meanings
ascribed thereto in the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce the Underwriters that may participate in the Public Offering to continue their
efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representatives, it will not, during the period commencing on the date hereof and continuing until, and including, the date
that is 60 days after the date of the final prospectus supplement (the &#147;<B>Restricted Period</B>&#148;) relating to the Public Offering, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;)) by the undersigned or any other securities so owned that are convertible into or exercisable or exchangeable for
Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of shares of Common Stock, whether any such transaction described in clause (1)&nbsp;or
(2) above is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or publicly disclose the intention to do any of the foregoing. The foregoing sentence shall not apply to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transactions relating to shares of Common Stock or other securities acquired in the Public Offering (other than any issuer-directed shares
of Common Stock purchased in the Public Offering by an officer or director of the Company) or acquired in open market transactions after the completion of the Public Offering; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as a bona fide gift,
including without limitation to a charitable organization, <I>provided</I> that no public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock shall be voluntarily made during the Restricted Period,
and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock shall be legally required during the Restricted Period, then such
filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
distributions of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to limited partners, general partners, managers, directors, officers, employees, members, stockholders or trust beneficiaries of
the undersigned or of the undersigned&#146;s affiliates (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) or to any investment fund or other entity controlled or managed by the undersigned; including, for the
avoidance of doubt, transfers or distributions of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to a fund managed by the same manager or managing member or general partner or management
company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company as the undersigned or who shares a common investment advisor with the undersigned; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) transfers or dispositions of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock by
will or other testamentary document or by intestacy; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) transfers or dispositions of shares of Common Stock or any security convertible
into or exercisable or exchangeable for Common Stock to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned in a transaction not involving a disposition for value (for purposes of this letter
agreement (this &#147;<B>Agreement</B>&#148;), &#147;immediate family&#148; shall mean any relationship by blood, marriage, domestic partnership or adoption no more remote than first cousin, and shall include any former spouse); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the exercise of options to purchase shares of Common Stock granted under a stock incentive plan or stock purchase plan described in the
Time of Sale Prospectus and the Prospectus and outstanding as of the date of the Prospectus or the exercise of warrants to purchase shares of Common Stock (or any security convertible into or exercisable or exchangeable for Common Stock) described
in the Time of Sale Prospectus and the Prospectus and outstanding as of the date of the Prospectus,<I> provided</I> that the underlying Common Stock continues to be subject to the restrictions set forth in this Agreement and, <I>provided further</I>
that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any public filing or public announcement under Section&nbsp;16(a) of the Exchange Act required or voluntarily made during the Restricted Period in connection with the exercise of such stock
option or warrant shall clearly indicate in the footnotes thereto or comments section thereof that the filing relates to the exercise of a stock option or warrant, as the case may be, that no shares of Common Stock were sold by the reporting person
and that the shares of Common Stock received upon exercise of the stock option or warrant are subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters of the Public Offering; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock that occur by
operation of law pursuant to a qualified domestic order or in connection with a divorce settlement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) transfers or dispositions of
shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to the Company pursuant to any contractual arrangement disclosed to the Representatives and in effect on the date hereof that provides for the
repurchase of the undersigned&#146;s shares of Common Stock or such other securities by the Company solely in connection with the termination of the undersigned&#146;s employment with the Company, <I>provided</I> that the repurchase price for any
such shares or securities shall not exceed the original purchase price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) paid by the undersigned to the Company for such
shares or securities and, <I>provided further </I>that any public filing or public announcement under Section&nbsp;16(a) of the Exchange Act required or voluntarily made during the Restricted Period in connection with such transfer or disposition
shall clearly indicate in the footnotes thereto or comments section thereof that such transfer or disposition was made solely to the Company pursuant to the circumstances described in this clause (h); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the
transfer of shares of Common Stock, <I>provided</I> that (A)&nbsp;such plan does not provide for the transfer of shares of Common Stock during the Restricted Period and (B)&nbsp;to the extent a public announcement or filing under the Exchange Act,
if any, is required by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of shares of Common Stock may be made under such
plan during the Restricted Period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) transfers to the Company of shares of Common Stock upon a vesting event of the undersigned&#146;s
Common Stock or upon the exercise of options or warrants to purchase Common Stock, in each case on a &#147;cashless&#148; or &#147;net exercise&#148; basis solely to cover tax withholding obligations of the undersigned in connection with such
vesting or exercise; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) transfers in connection with a bona fide third party tender offer, merger, consolidation or other similar
transaction involving a Change of Control (as defined below) of the Company that is approved by the Board of Directors of the Company, made to all holders of the Common Stock and occurring after the closing of the Public Offering, <I>provided</I>
that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the shares of Common Stock owned by the undersigned shall remain subject to the restrictions contained in this Agreement and title to the
undersigned&#146;s shares shall remain with the undersigned. For the purposes of this clause (k), &#147;<B>Change of Control</B>&#148; means the consummation of any bona fide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third party tender offer, merger, consolidation or other similar transaction the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group
of persons, other than the Company, becomes the beneficial owner (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act) of 90% of the total voting power of the voting stock of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that in the case of any transfer or distribution pursuant to clauses (a), (b), (c), (d), (e) or (g), (A) each donee or distributee shall sign
and deliver to each of the Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter substantially in the form of this Agreement and, <I>provided further</I> that in the case of any transfer or distribution pursuant to clauses (a),
(c), (d), (e), (g) or (j), no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock shall be required or shall be voluntarily made during the Restricted Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the undersigned agrees that, without the prior written consent of the Representatives, it will not, during the Restricted Period,
make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop
transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of the undersigned&#146;s shares of Common Stock except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this Agreement in proceeding toward consummation of the
Public Offering. The undersigned further understands that this Agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, (i)&nbsp;if either the Representatives, on the one hand, or the Company, on the other hand, informs the
other in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii)&nbsp;if the Underwriting Agreement (other than the provisions thereof which survive termination) shall
terminate or be terminated prior to payment for and delivery of the securities to be sold thereunder, (iii)&nbsp;if the registration statement related to the Public Offering has been withdrawn prior to the execution of the Underwriting Agreement or
(iv)&nbsp;the Underwriting Agreement is not executed on or before July&nbsp;31, 2025, the undersigned shall be automatically released from all obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned
further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representatives and the other
Underwriters are not making a recommendation to you to enter into this Agreement, participate in the Public Offering, or sell any shares of Common Stock at the price determined in the Public Offering, and nothing set forth in such disclosures is
intended to suggest that the Representatives or any Underwriter is making such a recommendation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement and any claim, controversy or dispute arising under or related to this
Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only
be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d92808dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g92808g92p61.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T: +1
415.393.8322</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">F: +1 415.374.8461</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;10, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cogent
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">275 Wyman Street, 3rd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham,
Massachusetts 02451</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Re:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cogent Biosciences, Inc.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-269707)</FONT></I></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
examined the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269707)</FONT> (the &#147;<U>Registration Statement</U>&#148;), of Cogent Biosciences, Inc., a Delaware
corporation (the &#147;<U>Company</U>&#148;), filed with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), and the prospectus
supplement thereto dated July&nbsp;8, 2025 (the &#147;<U>Prospectus Supplement</U>&#148;), in connection with the offering by the Company of up to 25,555,556 shares (which includes shares that may be sold upon exercise of the underwriters&#146;
option to purchase additional shares) of the Company&#146;s common stock (the &#147;<U>Common Stock</U>&#148;), par value $0.001 per share (the &#147;<U>Shares</U>&#148;). The Shares are being sold pursuant to an underwriting agreement, dated
July&nbsp;8, 2025 (the &#147;<U>Underwriting Agreement</U>&#148;), among the Company and the representatives of the underwriters named therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of specimen Common Stock certificates and such other documents,
corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinions set forth below. In our examination, we have assumed without
independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted
to us as copies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the
opinion that the Shares have been duly authorized and, when issued and delivered pursuant to the Underwriting Agreement against payment of the consideration set forth therein, will be validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of this opinion as an exhibit to the Registration Statement, and we
further consent to the use of our name under the caption &#147;<U>Legal Matters</U>&#148; in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category
of persons whose consent is required under Section&nbsp;7 of the Securities Act or the Rules and Regulations of the Commission. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Gibson, Dunn&nbsp;&amp; Crutcher LLP</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gibson, Dunn&nbsp;&amp; Crutcher LLP
</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">One Embarcadero Center Suite 2600 | San Francisco, CA 94111-3715 | T: 415.393.8200 | F: 415.393.8306 | gibsondunn.com</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d92808dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g92808g0709130424983.jpg" ALT="LOGO" STYLE="width:1.32083in;height:0.551389in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cogent Biosciences Announces Positive <FONT STYLE="white-space:nowrap">Top-line</FONT> Results Achieving
Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with <FONT STYLE="white-space:nowrap">Non-Advanced</FONT> Systemic Mastocytosis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151; Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks
<FONT STYLE="white-space:nowrap">(-24.3</FONT> points vs. <FONT STYLE="white-space:nowrap">-15.4</FONT> points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for
placebo-adjusted and absolute symptomatic improvement for this patient population &#151; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151; Bezuclastinib demonstrated a powerful
effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo &#151; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151; Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use in this patient population &#151; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151; Bezuclastinib NDA submission to FDA expected by end of 2025; strong financial position with $237&nbsp;million current cash balance and
access up to an additional $350&nbsp;million via recently announced debt facility with SLR Capital Partners &#151; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151; On track to
share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025 &#151; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151; Cogent to host investor conference call and
webcast today at 8:00 a.m. ET &#151; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Waltham, MA and Boulder, CO&#150; July</B><B></B><B>&nbsp;7, 2025</B> &#150; <U>Cogent Biosciences, Inc.</U>
(NASDAQ: COGT) today announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with
<FONT STYLE="white-space:nowrap">non-advanced</FONT> systemic mastocytosis (NonAdvSM) demonstrating clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including
patient-reported symptoms and objective measures of mast cell burden. Based on these data, Cogent is on track to submit its first new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvSM by the end of
2025. In addition, Cogent plans to present detailed results from the SUMMIT trial at an upcoming medical meeting later this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We have been
eagerly awaiting this day and are thrilled to announce bezuclastinib&#146;s performance in the SUMMIT trial, demonstrating clinically meaningful and statistically significant results across all trial endpoints,&#148; said Andrew Robbins,
Cogent&#146;s President and CEO. &#147;Our team is already at work on our first New Drug Application for bezuclastinib that we expect to file with the FDA later this year. We are committed to providing bezuclastinib access to the thousands of
patients with <FONT STYLE="white-space:nowrap">Non-Advanced</FONT> Systemic Mastocytosis as quickly as possible, including through our recently announced Bezuclastinib Expanded Access Program.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SUMMIT trial, which was designed to assess the clinical benefit of bezuclastinib versus placebo,
achieved its primary endpoint with a highly statistically significant difference in the mean change in total symptom score (TSS) at 24 weeks (p=0.0002). TSS was assessed by the Mastocytosis Symptom Severity Daily Diary (MS2D2). The bezuclastinib arm
had a mean reduction of 24.3 points in TSS at 24 weeks, versus the placebo arm which had a mean reduction of 15.4 points in TSS, resulting in a placebo-adjusted TSS improvement of 8.91 points. In addition, the SUMMIT trial demonstrated highly
statistically significant benefit across all key secondary endpoints, including reduction of serum tryptase on which 87.4% of bezuclastinib-treated patients had &#8805;50% reduction, compared to no patients in the control arm (87.4% vs. 0%;
p&lt;0.0001). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;People living with NonAdvSM experience debilitating symptoms with enormous impact on their physical and psychological quality of
life,&#148; said Nathan Boggs, MD, PhD, Allergy Division Director, Uniformed Services University, Walter Reed National Military Medical Center. &#147;It is extremely encouraging to see the results of the SUMMIT trial, which match my own experience
treating patients with bezuclastinib, as these results suggest there will soon be a new standard of care available for this patient population with significant unmet medical need.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All primary and secondary endpoints demonstrated statistically significant comparisons in favor of bezuclastinib over placebo: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>SUMMIT Endpoints</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">P-Value</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(two-sided)</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Primary Endpoint</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mean Change TSS at 24 weeks</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.0002</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="6"><B>Secondary Endpoints</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&gt; 50% Reduction in Serum Tryptase</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&lt;0.0001</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&gt; 50% Reduction in KIT D816V VAF</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&lt;0.0001</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&gt; 50% Reduction in TSS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.0142</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&gt; 50% Reduction in Bone Marrow MC Aggregates</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&lt; 0.0001</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&gt; 30% Reduction in TSS</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.0004</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mean Change in Most Severe Symptom at Baseline</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.0001</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of treatment emergent adverse events (TEAEs) (98.3% in bezuclastinib arm vs. 88.3% in placebo arm) were of low
grade. The most frequent TEAEs reported on bezuclastinib treatment were hair color change (69.5% bezuclastinib vs. 5.0% placebo), altered taste (23.7% bezuclastinib vs. 0% placebo), nausea (22.0% bezuclastinib vs. 13.3% placebo) and ALT/AST
elevations (22.0% bezuclastinib vs. 6.6% placebo; <U>&gt;</U>Gr 3, 5.9% vs. 0%). Serious AEs occurred in 4.2% of patients treated with bezuclastinib, compared to 5.0% of patients treated with placebo. Discontinuations due to treatment-related AEs
occurred in 5.9% of patients treated with bezuclastinib, all due to ALT/AST elevations and all patients fully resolved. There were no hepatic AEs reported in any patient other than transient and manageable lab abnormalities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In addition to its impressive effects on improving patient symptoms, the safety and tolerability
profile of bezuclastinib is very attractive for a patient population anticipating taking this disease-modifying agent on a chronic basis,&#148; said Lindsay Rein, MD, Associate Professor of Medicine in the Division of Hematologic Malignancies and
Cellular Therapy, Duke University. &#147;I am excited to see these <FONT STYLE="white-space:nowrap">top-line</FONT> results from the SUMMIT trial as bezuclastinib represents a new, powerful treatment option for patients with <FONT
STYLE="white-space:nowrap">Non-Advanced</FONT> Systemic Mastocytosis.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Complete analysis of the full SUMMIT Part 2 data are ongoing, and Cogent
plans to present detailed results at an upcoming major medical conference later this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cogent remains on track to provide top-line results from both
PEAK, a Phase 3 trial of bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (GIST), and APEX, a registration-directed trial of bezuclastinib in advanced systemic mastocytosis (AdvSM) patients, during the
second half of 2025.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Webcast Information</U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cogent will host a live webcast today, July&nbsp;7, 2025 at 8:00 a.m. ET to discuss the <FONT STYLE="white-space:nowrap">top-line</FONT> data from SUMMIT. The
live event will be available on the Investors&nbsp;&amp; Media page of Cogent&#146;s website at&nbsp;investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived
for up to 30 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Inducement Grants Under Nasdaq Listing Rule 5635(c)(4</U>)</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cogent also announced today that, on June&nbsp;30, 2025, the Compensation Committee of Cogent&#146;s Board of Directors, made up entirely of independent
directors, approved the grant of &#147;inducement&#148; equity awards to three new employees under the company&#146;s 2020 Inducement Plan with grant dates of July&nbsp;3, 2025 and July&nbsp;7, 2025. The awards were approved in accordance with
Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, nonqualified options to purchase 92,500 shares of Cogent common stock. Each option has a
<FONT STYLE="white-space:nowrap">10-year</FONT> term, an exercise price equal to the closing price of Cogent&#146;s common stock on the grant date, and a <FONT STYLE="white-space:nowrap">4-year</FONT> vesting schedule with 25% vesting on the <FONT
STYLE="white-space:nowrap">1-year</FONT> anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Cogent Biosciences, Inc.</U></B><U></U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cogent
Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the
KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company
also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases
targeting mutations in ErbB2, PI3K&#945; and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at<B>&nbsp;<U>www.cogentbio.com</U></B>. Follow Cogent Biosciences on social
media:<B>&nbsp;<U>X</U></B>&nbsp;(formerly known as Twitter)&nbsp;and<B>&nbsp;<U>LinkedIn</U></B>. Information that may be important to investors will be routinely posted on our website and<B>&nbsp;<U>X</U></B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Forward Looking Statements </U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the company&#146;s expectation to submit an NDA to the FDA for bezuclastinib in
patients with NonAdvSM by the end of 2025; plans to present <FONT STYLE="white-space:nowrap">top-line</FONT> results from the PEAK and APEX trials in the second half of 2025; plans to present a detailed data set from the SUMMIT trial at an upcoming
medical meeting later in 2025; the potential for bezuclastinib to become a new standard of care for patients with NonAdvSM; and the expectation that bezuclastinib&#146;s safety and tolerability profile support chronic dosing. The use of words such
as, but not limited to, &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; or &#147;would&#148; and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in
our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the
accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking
statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption &#147;Risk Factors&#148; in Cogent&#146;s most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> filed with the&nbsp;SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly
update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date
subsequent to the date hereof.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact:</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christi
Waarich</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">christi.waarich@cogentbio.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-830-1653</FONT></FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cogt-20250707.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/10/2025 2:56:31 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:cogt="http://www.cogentbio.com/20250707"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.cogentbio.com/20250707"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cogt-20250707_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cogt-20250707_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cogt-20250707_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/10/2025 2:56:31 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cogt-20250707_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/10/2025 2:56:31 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cogt-20250707.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g92808g0709130424983.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g92808g0709130424983.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 'T# 2(  A$! Q$!_\0
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, HHHH *0T44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g92808g92p61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g92808g92p61.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MA"$N:*U-BN,V.6;X>>&W=F:TDR3D_OF_QKU5F^+2MS?@CE^J4NQK:3X>TK1
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M(-8\+Z3KLT<VH6Q>2-=JLKE3CTXK3#XVOADXTW9,FI0A4=Y(V*XS8* "@ H
G* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001622229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COGENT BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5308248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">275 Wyman Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">3rd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">945-5576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.001 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COGT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d92808d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cogt-20250707.xsd</File>
    <File>cogt-20250707_lab.xml</File>
    <File>cogt-20250707_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d92808d8k.htm">d92808d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d92808d8k.htm": {
   "nsprefix": "cogt",
   "nsuri": "http://www.cogentbio.com/20250707",
   "dts": {
    "schema": {
     "local": [
      "cogt-20250707.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cogt-20250707_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cogt-20250707_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d92808d8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-07-07_to_2025-07-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d92808d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-07-07_to_2025-07-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d92808d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cogentbio.com//20250707/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-25-157390-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-157390-xbrl.zip
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MT 5J/Y,FEBCD970T.AH@2I0K0.3D4&0+<\M(L&D]R.7348Q'HP-&'>$IT3B
M**G_WH$(XADUQ]#)(\C=003DQ\?'+$HW*)5^/8+.^B%KA5&;>V_EK/%X;FQU
MAG/>*$(U^I^&*SF76$8MZM2*TK6FLZ[AN5V@O^(5NIH+?%ZNJ:6>"HRXYNRO
MSY=?8[<EIP$ $!M05K6Q'MH^O#0BCL>.?(9?:5^&-%RE^3@]R#,REH!^DO:6
M&@)[-9&^NB\BLFJ-O8FX;2T<#FDX;//^=.._. .;(QWB/P[QY^_WBO_12O@/
MF!A]]5HR@[WV\IIH+D6[MMKC_G5Y0+ZJ-_NU$/)PN-/QYA[IO$:?7&OCHZ,A
M$U[74L]-=T67H8F+OI.G.(>XOPINA34*=V\Y5EM3H_62UOS#,+0&;BS.)TG8
M]FF_9[XK/LMHS_0JCQRLCU<0,X*@NGR@UV.]] %\&<00Y/1><K4R'=IADCC*
MNQJ,Y_\<;FWQN>$2Q-&&CF7;'O67@=:S@P]^KDD#PN';]&+' [%Z(9CG]T:;
M:MFR/#.B":]0__U1EY\T<5M>4&O9*O)*0-)3,B7U[WNIKUCV/$ND_V\R]F\^
M"A_Z>]=;&!ZY+J$U!P-[)VS3R*;]QF'YASZ-9\&5:-0JZQVXT]@%W*S7_L@'
M9MMQW6U?L7Z.V>8@=S?#@6^OVH5#/W\ 4$L#!!0    (  = ZEI0WE2W>P8
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M9 L7E/DLH'X$MT7'+^&2!7TXC2+XI-.D:E,2<4_"?JX:4?;?6/\UT\W#B^\
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M$_0/86C(/Y9L"7A=!K@ 70@7=FP#=:C;N4#$//UY^%K<"'Y/6=#PMDZ5QG,
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MT8;A(9^ME_*.*[6E?^5*OHMFOWA$[?D?4$L#!!0    (  = ZEI'IX%SP@0
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M&3H0HKH$7[3M0/X/6R%7T5YJ[K# /OJZ/F+?[(.<6/(W4$L#!!0    (  =
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M^R4+<,^#83Q6  =K;=YX%^[FLMSO"_GM[FP*5M"I^5UWDAU_SW%X;8@Z6]D
M+"I]J,R@=)66W4&_5(G66[::A%PURC[(]O<>'N_WL[HO?W.KZ@I6@JOE)!NH
M/Z6."A DIZ[-/L%6MLNZ[&"_\##B).-;.Y'$=^"%<"M<\J<DP>+[.:'DP7HY
MEU:J_^$5[;K@.^6!N383K!MJT'WU,.A@/&??U=M2(P1" LD^Y9TETE]YAJ6;
MX92J'*7I*WGQ6/^(YXL7,EOY:6^8$^?C^8C15^L[._[F.[N9[\S#[KAJL);O
M35$2@#^2&B%WT#T53S)Z.>J+/ R8D9?;M 6EA$PGU+>(#O@&C<@)D"6BNV"\
MLGX;KA-!EL($/<,.4!VTL2'.[J.+YQE8&M2G!%L=Q&'L?KPB&[>NPS16*B@,
M)[U=$0#B6O4LJA]!+7*A>5"K35_!Z>\/LX,[$,R+!0N2]ZR^L*?E3)L26N4B
MD(='QWNC?6Q!GL"_SGK%(GL)ZCQ"2?T]:R;97\DOLVH$ZW^?(^YA\AOEA$?
M.3I8IW-HK'ZRT\$!&%L[@O2Y**F7K'0)\:->IQ5/BB5N700:<>+=<183^;K]
M2JDX9":^$_.\<VOJT]R2YSP+*;V3D.&2*VP^HGJ,J\AF*QI3^T(3, N2$C:[
MHCJ1F1YJ#<1PB4W1"MJ)SQ.4LM,8[$L6O\XLO /J_NNO_>2-U]%[TC=LVOM0
MWS^P(]'&P9J&H/.1T] YR(L_.V1CCG"XO@+DF,""1]?:C-U4E,(B+?P(,@Q=
M;]6XT%+9>LE%DO(A:E]Z%_IF7>\G__..I<WD\/]^^9-L&N)3!EHL K,PG>AH
MAS<:DQL?^,#8;0>P]0=_1X;=B-FIUB=>RF6I=S7TF>FLU%'+MQLK:LBY(;WQ
MMIWE[LZMS;,Y]!SV2^^1Y^24SZP)TNS;]A!LY@WA-HNJ=5B[W&-1F#&S_H*\
M09S&7$66VX.]R7Y_XL =\*,6K)!3QQBU>R$9;@P7+\%WD1\#S1*T)R4GK$:Q
M-2G/66%LPK49Y4"/RR+4[G@U8=QPE5>0T+ NEF<R 1 A%-&TI>.<^\:24AVX
M)3T!#9$LCO-^AHN4U*?O_L7N"T:O9[Q0R@<$]F@2<AC2TZE66"A$K),#+BG]
MPP^$/Q%4)W=#C=[S$28"IR>Q7W'SUB@)R$6X1;^>,8P^G_"XJ,?+.?IDQDY]
M, G8" R!T'(34@Q:["0QR[/)W?BGE\M>%\W&=%+!SAH2GN2=Z.AE%*UAYR[M
M%R$(^4 V)<%SV,KECV)DK%@L9X%BMJ@E>]5H756ME@ S.A\$$D?22DLULJX;
M'<Q%?-NX '\;<)2;0A+[M-%6]_L:R.OE]@UET7?@^_(2>4GK"'C,<P6[/,V_
M29U/(]:!+<AN_]&XY@]V]G?2"_6"1#MB8Q!XL$^*9Q<_\!#0C 1XE5(%#Z34
MVL:(.4$K:BFRS@8-ZDRY 1ZF!810Q]> I-DB>\2#"+O&EP9:PEOS=W$:EY<]
MFM[7Z)(Z^>:2NMU><I\8A]YXUA&18(Z0#HMSS$EP#29=2J_$\B5"?Y-TTNXE
M(N0D:O&K\ P6):<"%2=ODDY!GT+5 .><(K98D-^ MVZ5RMTGC5);=3G4GC7X
M.I7D4% VJ5[A;K!,X139@>RU7D9=$'^3- WB2")NHL'^X:7=@8:P6BFC+AHO
M>9!]47Z?^L(K!?BL.SUX38%7C^,A@$GQZ"E,-@4ZX,'V$/P%CMND<6@ZJDZD
M[*;&.G(R+#_/FX,WGV:YJQ$]OG?O.*@179_%9X&G0A6=E$&<B D\ HD'!9OW
MCMWU0"S1*I.B(GFJ24[@"?S%C_<>VB=]<8T'E/^BQ__/?W8EPY>&GLOV&?[=
MA.5KG_'("&A_>DP2%NZLIP'/OLSJR<&LJ@CBU>GP/=K@:!4:D<<_G'K;+$SX
MQ/AP\.C1RSYOZ/[M@(IUV:"SV[#%?5-Y;AO!['7#"**<.O['"?#,%B?+/.KE
M-UH%&3>Z1M*-9RM)&EO.->J,?H$YE51DKH&CN9C<6(+*(@(3*30P.2U+JEEI
M15(&/5W.T&2@,Z]7UASCICS3%2N"".@WM?@0[*!G:T,Z$VGJ+%PQSE&SR4;(
M=G'=.) "! T2TB$B?@@^F]JDEYFDHSBS-XI7]&2@4/8$L\*8@;I:5PSI9C.V
MF6*S\<M>RA%B8=VI;W!,>#YQAY=8X9>*')M"9#IR:<8CQM%!<B\4"VF.>"TH
MA:3Y*TBZO+VLJ-<KV&,31$&!/U;3EO]UF<,7VRYF,!5H@" ?41 YZJSJNZI^
M2-[S=VS+ ((-G,"TJ+(4(\8>?DA['N<U+BML4IP.:BMI4&0WY&;RZ.?7Z#F+
ME8,NINF0W-*!MM]NAJ/E&7*/NJX(.(V[?J?)!V#K<%?.X;?DM@<:V-T95?,1
MH<+,"(O&,QH$IEHN6LYUB=,D^F.*Q=Q#*4<]C@C*KAX7DF+B^.7B?-6P%DQT
M5&@:16:Z05SX[*\T650S#$H&X)Q\EJX?6--I%:9=QT@%"CNMKNE =FX0Q%(M
M.:]0@.BA(HSU!+AW5DJ3776.Z)%X6G3$:].IF&;?:N/X%_AGD:3:Q[B'J$"+
M\R7,QA,=C!.[B7=W/$1*4F;MDAKYTANJ.F([0\QH >)JX0 FL+,$+3C+%^?H
MX"R7"."Q17OI_ !V?^9+K&0D&*5E0P<O.X?/=;]X;!+-V2<50!H5T ]/T#BI
M=;K:3%?_N@#V0TU9]!?<QA@C3O7$_1*[(B=!1VK,2B$H"/Z^I'O+"X\C5ZTE
M$NL>XCPT9(%R'@LY#$Q0-^+4O*\'[1QCBN=*S:ALM)+2Y+QFK=TUP@\1<;F,
M+ 0\=6K8+R_>OK/Y[5=;"-\=&$E0"-<MX5=^Y)6#AW@+!Z*9\P1S&R;3.WR9
M'Q\&MH/H76XX/]</7MQ@"L=+N!_5G UG$%T*?BDODH=Q0$S\^NKMZ6G0LR3(
MJ#=NK2)G]V@@]<ZY$1)6HA*C""E6S<[PHA&MG0M,).94DS!FZ$]!0R"'MTQ8
M6F; V:ZTV1;6 * E:TR:#.Q__7H^B:ZT'!E6/>2?J(5DC44K&>->?Y!<><UR
M0;=AC9(/6:J#YT98FF6;G;&[#\LT733NJ_5KW?_FU[I9JM526BDSP^0>/Q@(
M(A%B\OU8ZX\:OG&5A!3-8)6P$<@<JD>OD>LL3?G(2X8%I<R.5<?IG+H("^:<
M3\B*8:[DJAGJ')&*I<+%]%CI G7@(K90>1A/B$KDN II;0>TJ*D;74F!?4H4
M%_S/Y>1,BIS7 D$I*P!6RCW(M)],11)L&,YQ=\?A.:9^9U2E2AS&>:??;'>3
M%B"+LQZM)])X IU$R[_X?1(KEEFN?95\=P'SH>9N3'Q]_>-#B)5#O.A?'/]S
MLAT6%NNOTED/5H T3Z-A;#.]"FE)(!;S&UF9H-3BK/^T9HH]/X QUL6=3TAH
M=A/(ADT"#JD-:?\:=Z+0.D$.1+Y(T>RI,.RW;"7>H0=I<GSOZ%%J6 H#>IFN
MBS%@+(]&'J4E=F8%0^B/$I?TBU0&$I6]]51I(GH^2(F:E+4J]U[^@5-Y^/W#
M'W[<CU6-(!'OK9Q U+B/7-Y2IQ.?+3NI_&OI=GM.*U_,0"%/NUO)79A,V2'<
MMT50+]930+0U[BX;)P$_,:4ZEH4,4Z5#A7=:D&F_J T=I2H(*:"<< ]'4@"M
MLA3RCS M\JU,,3R)K2@Z:(!)7BG\T<^)J'G9*+BJ6!91BZ5(&)A+B)!6ID>F
MSP34?.+2!#7\1SD#0N%<?5]A6 JM=26(E!MA:Z6=IXO5<)% IS_;=5:@$XJ)
M)]SY*<@T\C\(9)(X'16DJV@]Q)T[G-5/82K;0%L^%6NUR87RF@;K"QH@9SI-
M6<'IOF8WQ '6=R^LQG>"[F2*]WLA)1X>A,"@U@WF/U/9O:1W.- P7N?CT.W;
M<1T)QM<B(U.4G&!4B5'-])PQWI2*'A5T'=3"5K68O8](TJ$D92(&8S?;\5CP
M5JUCVN.]<V2+JL<4-+VR..BX-<#9" U=<MZ<=A)JC(I1%7S\6J&>*XG[8_C$
MJZ>N=J?A=.\9N[/>2K(83N/54TONC)' "V45&M]1332_8"'^!ZX)PYRD%+I"
M)?-KX(T+"1JZWLR<B2TZJH'>DQHV8FF4>.691DK(H@98AUFQ$*@^S_$-4C:P
M)Q7-/=792O]SS,KXLRI*2F!" 2];X!.ZO3\^M_!\['AA9*B?BWJN.3N(%  T
M2QZ(Y,D?3]\+GDGRZLGW?SQ-I!EJM2 4*T:&1(\6,6S)<0)C(?%#XA;]VZ/#
M^P]CX: S)6RW0$1\\<C FZL?:10CLP5EHD[YTPVA:OTY1ZJ&$B>P7$.=EBCI
M%Z<3?AUK$B0_2Z5Y\&QSCB+3U1%0<:4ED;6DM%S@HR?IR0G]7_>C"D86'F-T
MQF\682[M?JHH'D#0Y]4E?M]#&2N.+->UB7,J6-)4S,_N;'BQE L!/%@++Q,=
M$.\1$2.&)F8>Z &G@BW,@!G.LKH;BB3=*EN1!)9[;R^+X@.;1[BE;3P_%K[O
M#$E=D%ZSPL;OJ+.3^8Z0 IR3&;>/"7;!2A.^YAB"17+!_XI\P96<%91EIHD;
M(J8)T!B5 ZXT.+D':N)*HZFM5B5WRR3[CA;5OZ*:!+?WE%#V95'R33X>Q@21
MQMOJBY[VG*:4-PII]=."TCS/-FB$U/@*H6@D:<GNN"2]/,?*A1&QL%F.O5Y1
M^W,1)-@<LS=?K2_NP3=?W,U\<=$M@JL!UTML8@1/%CCG/*NQ!03?+1+K8#O@
M+9Q(2+3#1%#1-O<1OV&)K^]F&FWT,'DC<51XEN!HI24,4+._6"Y/O^=.)'OP
MU?A>/Y=9@U475K7%&M%5]1)<QKJKOV?D)C?\-=B!:"RCGZ2DO:Q9&\8 ERRN
M8=;2PV=]R:2@AHRHE;,Z(JD""O%6*H?#T5;HV+L*EU+NW[.%,C4SW UT+AHH
MFSM*"!1775C_(LQ7/[^N?D*Z^@=2?-!3P%"U;Z0D!%7T3GNJ;')1&(8?'Z37
M% )10(?7Y*[N(5.H7E=^PF(T!*B6\_98G8Z(F@J#T^[6#2 QL0 *1*1XRJB[
M@X-+893!OO5(GH<ZI-T&H"[1V1JQV$%)VFZ/DLZ-I]W(O6^8]XA;M]*]7:O"
M_WAX[UY'A0].M*/)JR=:\3TG.7;117J?Y;:_:KP$,Q$V2)TNWC 0ZI@[@!*7
M*:@'G.1Z_-N]PY/C^_'T?>2T=\:?_R;<IYOP-ELYPGD!? SXY8I-5?V+%0^.
M93O5EGQ/,810Z0+:SE\P7:)*6\P%) M/UI57P?,XKW]4]<?DN>WR,)$).?%B
M&93.R]P>">"[VR/L/]+1VN3HWD] -]GA_#"-OHS::HI,\V]+F.+1/70WH].9
MNAM+VPE!K:$4P])S:X+<='^>$*1&I-;2H,?W==#,["/[7C4G5BO"^FF1KR%-
M0%)+O !>Z'G6>6"QVU:@PO?=E8GEZJ$$][^XR6M);H-)]3GI#C,H(L+KSN3S
MDI]3K!Q2M0/3=NU-\<A$\0L*;<)\6O*E;:3<2KNF6.H5-R-[*R-2/EV>@0;$
MWWAT<X+^TA&Z#UX6T8QW=T8!<H,FJZ)*$_25@75AUDFI#IBF5UCP+@AXCUU_
MM(MHU$V7N&'6LI,XH!"WU=B$YHP+OD>O2W56A+O./50.DWC%\$M'YU[^Q@O1
M)@[1)&#J6WXXO>Y%226NA$5JF%7,8$/JU!C(N71/A^J3E@Z&XZM9,D&NC.Z=
MU D>Y:*NH4'@3\(KDE,;GL\MHQ^0C'[NG; ]_C=1V-[XB+W38L-NJ7$NM#J<
MXWWJ=VGH&?6,&'H#C5TEGBI' EJ"V4-4$:@[43D%HL:K+9V?UF#!G/- "<[<
M9 V\'<?>_<;$I'Q)/GS-S HB-6M4<"[J"=7MKQC6_>$W'\UM"YYMKU+/G9A6
MF'A(,3P-ECKF\-.Z1)>'GZ>BB+JT<H&_M+K6$F)'^S;E?>#*.*4![29!=A,(
M+=]6B7NU+=E32J:U@6\D]*Q \7ET.HPR[[ZG$V929/'J&K!ZM[MDXSZ6,&^
MYT"^)X*MK(?0'&S4@X+LJ(%A=0RA =JVA9KV.SCSO:BE"J6 KOVX"_Q'E96X
M/"K9OW]R,OB]?55]8ICML"8/Z8!9ZF.7T2;*3]/=1E;OO4(=PL>'.\7Y)VZ7
M1(Z;/"+$\VRFF4LG^Y?0+O=&^\G[Y:C!+?!%J5*I)#4&UL2(A15#Z'9TP-V=
M%P)Q4&OTPF$D5F.*^3,(EJ)EB1DU 7XSJQ;LSG%U_EF ::*O."M#N$H:U0JV
M#CK!8TCF68U594WJU-C4C=T$%89;U;[T= 7;W9'0,5HRUC&)8PT5^^'3Z79>
MKI1ACQ55KG00=J+^$(KR1X24N<*(\P4Y@\<*(2/%W5U%R(=AM5MI!JIMC?T,
M%9ALR\Z 7[9NC%,<A^*[+A.G5]T+F]UQ&PJZV^%CE )X5KK8:4^U7]QWOC+B
M)R26"-@(+FDVJBYRFYLJKSD=;X/.&5'SFO@[NSP1<(?#[90]XY7/GG5W:N^I
MFUS #W&O90J9SS[ABBADBX5@UBJ<CK<C*D9SHZ"LA RX!([1I_WKOO4;)]N(
MI(P/E.U+/1,\,L:,=GS.H>F9<^=8<XVBT&>PH,$,\S6U$CY]*I-\4=]IT8OK
M.[@ DYM<@!*;GQ6EBH,207C9,:\%-+.\;9G ?RE&E.G^8ED*]?Y'-E\\3I[7
MRW:,6T0]!Q&^&GN1H&T-EIVSNCQ G]ZRR-2A1JRDMR'TIP=>-Q6!KF$N,$F-
M]R.Y:%8)%R#;U#4GF*MZY03WW4OF_$9GENB1X:%4U00T<>3!XU;/@-QUE*S-
M9Z +MRVI+:*11B$P(Y^27I=<A ^WL76;/7QRUSF%?O7HRQ8]3V_G%#9>G-]@
M7_^9)J_S"X08>UZ=P__^G-<U G#\,JLNFH\KQI]]"SM>I<G;P^>':><"A6ZC
M_X^=Q=\'*-)A?YAV9**"R/9KL-D[$7OP;IN$$ 1Q4Q[@L9/$38<X&EP4P]+H
MK2V.,(E.D%R/C<"!9=H&V,T:GR8<FZE%P5$)A%GL(!4+[%]!RKHL.FJ0-&S-
M7KF=EZ2OK[@$,NC?-K,H>;"I>Z9C CFSJO%2$ZP'6O?PWM/JI Z*I#)P^65C
MH5U(UW3?(D1#5PZRS6<X?13W4XM';)M:.%*&?$5)HY4Y*2::*7:[:<GYU?K*
M?OCF*[MM7YF[M5NJ043=/:(Y")$Y3*& .^5J#YB\S7)BHR-Q((\M! [R]!BV
MDF!8.5YD6WQ^27%[)O@>F^0MA1ZU#T:?L[S'3:[2UHM%^Y*JH!NC1/W2LT]D
MAM*8_ )K.G%C2=2:;ME-JD9; $6CUKAW3"GF[&J!;D+@BEE=S%:!:#2CBC.
M(^Q@LZ$)*AO52' =2X7L<?1@7?8W&R#[L=-*W,R5_08WQDKJ2JK'&(S27&D,
M,GD;58G J0)]FAM3'&$';4:2D+U;M@=@52J@!)*6[!]A5D=YC=)-A6GO#N[9
M.:NU&]<VJ\8?#Y8+!Y/A;'=)990+("E0VGD"KP><TY,_GK[\=%Z,BC8YQ52\
MW1U6#E),+!?G>R=YR= ,Y25*F^W4X,1Y^#A6$/BG@PP>F%%?.\FEB!B=+>WC
M_E#V8Y).4#3:8)S>'VAF5=71>[YS49K$H>IN1F7'06$949@DMO&$7H<GY&M[
M@KQ3&[>@,#Y\>LQVLW9(Z%Z#N["WBNWLK6OQ?^O045WR')3KGMYOSM>E_C)Z
M5=#/^L*^:_G<6F3,ZW.YZ\JBNSC7/_E<KQ.;[V8T>5??]8+QNSL#T?B.*Y1A
M##8GL=@ O(N7].EB<LW6#ZE3=S'4G]:=V%# 5'Z%ZC =V(TOYI KO#]E^^H.
M<4*ZPBSSL\2G*MM+NUYH#_:P>8 ! .$-=3ZG5IP##NZA#/2U*89?Z #P!*[@
M4;I-5RPC0O82?XRY<<-$?W7D7A:-RYJDU#\14W+'=!=LC+C;#4(CO?\"9Q<>
MWM6<LLG-?+*L:ZZ_J;>TYWFXYU=+\+CE+;_81U_5K7I@8_?=]@[8+WUU7(^V
MZYWC-#K'K]'%]>B;B^NS7K"+_3Z72B^A]ZJINSLW]YDDFUPFO?8IW8D>O5GN
MAZQINJS+HCD?\*FM43;.S.7I\4*P+!UR0_3=[,_LC;BLHHI)E]'S+ZP-75Q1
M'TUOT83C$UQ;UW8;9AIGJ-VU'+U U26HN' AEH&2 G24FF"BNIW[W(8$5.X[
M6<<),FA,H9HN>&H>]A83";D)V'2MY,1>Y=L)39<N8% KR?ZPGQI")_C<R?4/
M);G^(B^S;A?7;BGHV#U)F]XM.F[$M&RN95C>.!/W0Z7<=2"ZG+K0'"@^-6;[
M8?H,A?XD]6<,6DR^*5O7! 9S=D3Z "6Y ;:.2DZK.K#KV?5$A!-L;#C#U:;Y
MZ2H[LQM15/(J44W-#5N_L5))MKOC*KFZ6^W8OZ_^ZBG^<G59.29KA65!<$\T
M%=KYYOJ31R?+6I]:$!9&@G^"7>HI$'N(Y@7,["&JIZ,<R)=<+W.F>$L. RZT
ME&^T_04EG6[>78V(<<(E 5KYD#?]S@?$]0A]4NR0I+@*^[P3P/_]Y!G[J&EY
M@LSEEUXX'_XM]+=(N\3;=9QG[E9)] %S[+E\W9Q!.$L'J-!*ZW8'2+;Q37C#
M-?'KG),YHXH<D*F[@M30OB=9'G]7=!R 0OBV?A)63@GOQ_?Q$ 9S['$E)GD_
MZFG&2?M64>4FP<O9773H'6_!]I,,(X+F@-T)#=4KB(',N)QT9[E$U.'_I Q2
M/V($:UM;W(-5)%3B.A1.N6F?;//&F5R!5N[B.D^P!(95+X)Y\/T: T@_C]L7
MB+;0+RC-ZRW%#5*]I4 DZ]V=^R<G.)MANA[<Y34G'>O//N0;+,,YNGB]KBQ!
M0)^C];0NU/ 5)_O\^,T3<MN9N:_6*AI8H\$7A)@/<E["<FT91(39UI+YC\>#
M ^9'BM7-F_TZ-84+XME_0'4W(91G_@GD-E>OR+V'M3 7XX;POCLNLD&4DK&$
M7+<)VS?4%9_(8$?=N&LNU_1,;[C&=9-'/1Z.S( &!]Z +?-6\$]8.T_,1":M
M93D^JQY]#VO]R+=P&&W4/B^ QDTY *J5:\)DTV&63B81B_(TH495H-%=E@0!
M6S8>PK=;GTW2%,OY$<M&DSU)PTT30<]=DUQ:K5UC4WF>;SN%K2^^XFYJVM0C
M^")5KW#MVC9MG]W%'68+$9!!UG^!4\(-<=1.DS)K&S1O3'.2:!VI+B295>49
M%^,2??OC'=+B;^OCJ-H-$> =Z*-39.*I&J!L#[ B[J&KID6-V#XF(M^/C&7
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MI"42O=-[[OCQKL]LPK7RF380Y76$LT(V395U+JENHR2'W3M U^JY _68#B[
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M?BZKY(RPKVJ/J9M)AGHTG[&C0S= /QUBN=I&0OPL%/8E4[Y^QB",A,R543C
MKL3T>.Q0D8]VD:,>UZ+ 0Z#DL*$HC %= #*2,[?E5?7<&<,",P:P24@4SR:5
M ?3D8SJEYYH8D1P]NG^T]W'_T$\UO 1FGCB_QF9VN^9?/V%^AT-UX)'&,@P!
M(JVTTY86>>*2"MLV4Q2OS=-_?OCSX3LW_>,'QX>/CN&>/Z;89A)_'4$</M.W
M=W?N_W!X0I^NZA#7(IS#S^]??:[EGSPZ/CRF?@[N^((+NS65N4FM)R@$P]@P
M)WLPH,C"'AWC_N!,C\@!X'-ES*S7L\4.$4HJ51A/5P".%SD5[ +G;Y8,$J+M
MC=G?0SES9)ECJ[#E[,QW-14N':#XD^MG=X==/SC"BVHR.4"-^"-J[C-1E&&J
M5)3 \7'X-%B?F-7:"C.XVAP^N^LL5HK_AS0Z=$].6.=!K19QQ,6V8JP=4"Z3
MT0Q6CJK<__UJ+0"PNO__8 '@@S(2.?%IH"<?3I^]?ID\?_GZ]?NWI\]?_?[+
M?WYW[SOZ^>WIBQ?ZLTSG/L[FV9MW+UZ^HU_+=_DW!["$UZ=OW[_\2?^Q]ACB
M,\-)\EY_>/=4_O%"/_S#OW\'A_+AA?_#?\M2>./]ANF#X?L_'NOOX7_>F2_]
MO_:NMJ=M<PU_K]3_8&T[$DBF ]+2E6V5H,TH6PL(Z';.AZ/)B1UPZ\29G4!S
M?OVYWYY7VX$ (:1E$ATXCOV\WN_/=:DN6'.6$OSF=G21IW$P8Q>\QF'X*(#1
M@*$]P,E^_2?F!T8%%N4AQDX9FC:Y[;$>;#WW77M_[]TI]'++?6S34^ZI5V0F
MU,<Z4%;?N(_.3-;V?7,1?7^].]FV6^8M12W#JG?0MZ\MV#;P4H?./)M+7_#(
M*'3C^W7Z;T8+]<?R1PZ [8&2&J#46\#PW6+L#L KWG9ZL$RM)]NA,8YG^@+_
MH%1^S<K(6B]6^S:-/FU4KXXZ_79E_4)DX@[!10I^-%N*Q,7$)V^_%K'?G#%Z
M%/P/3O#O)H-/\/$@V!W#HT>C917_U7XL4Q]$"7R(!M$9H3Q(@<77(A+J,K*/
MPN#!"8/?$6@$@4RQ*"E95E'@]V*9>B""X"09X/G6KU8>-!<\/$J%!R<53L[3
MB^ TFF18B/#A[;**A4HWEJD+UY8+&*UD1W&>196'7M&HP-CHZ/64-.Z=U!<H
MOB2GUHWI[)%]1H-Z.F"V\RSTJ\3*]0EDL'G.*(&OVXH3I_.;_U5-^WICS/,.
MV4O@&L\+OGG7?OOQ?1LFGO7(T:(")3Q^\XJ4^*MM2N#DIU?7C9RTW,C)]-_G
M(3A_JI&;JHT'AW\=[SBS&;CS%]0N)T\9/EO'.SU]B(?#LVBR3>=&UKI)EGF-
MNJ(#M/(L0:16WM72OEGFJVY;=HLWYVH8KNXAM>^ *CSYA7F/_X]8I;_L'K^6
M,PBG>(@)_SY2Z(K:%KM:9_D9E-T]DBN_?O=]MYLDO=YW]Z!>9UT<<@D%%0T<
MBE"[U&--79Q)-4V+?MUL4?#:OX;%4'^C)R9?A2]?OH2?GV9[Q?U:2@]C*NNC
M%@]A$K?"K2W\>7GS2?QV=^@TY_,A3.[S\/ES_'GQN$.OW*%I+SGIINIPP\.9
MPXVPU6KASZWGT YZ?$%KHZ%?=V!NW-2\(I\$+8\OON5A+.C%O_91$/J[!^S"
M4R0)W;Z-R=JPJ.'9ZE[7B+S6]H%O;VZ&F_33NMX3:M[H!T26L SM! '*]M<V
MOHEBM$4$"DRDX#[#0[CS]C^T@\/?@I,=:,;1\>')4?O-Z<>3N04N[C8 844V
M_ B('R&Q%XJ2N;2D@E^#)AFKI::J.X$UYN03Y'=>.QO/;/%@?W0[J3O##(-B
M=MMT5(MR2^4><?#[.)MH'NC-]<T7@1M45Q++7I*F,5N/:Z"Z!C8?Y!I P*MA
M4C#,@\N9O1W\\ J4]C5FWFKF5H,LLNV#F4^H'-2RZ C1]W9@%/&T*/I<6F:'
M]X7ET9!O-%.=; <M97XO;?TY*_Y'S7_7FK_][W?[N_NGP<ZB]/YOA\<?4.]?
M><K^_>&;/]8^'JDS]N_;IS#"]]IJ&3745L'??UN::IZI18Z?'A[O[1P$)^TW
M'X_W3_?;)^C9SSVK^+[=/MX_^",XVCD^/6@?FY?.\:3TWL>]O?;!N_;^!ZNW
MX4V[>ZN3BCMEE<U+0;O5I%OGCITR'7UDWA-3Q3:9^_IK@DZ9^YXCT)2FQ3_/
M'K]H":2L0I)XOGXK'):Y-[@19F3]?F;I;L7%;!NB D0S[RW8!',S?]'S'OHI
MY2Q[( V)7GY[2G>;K-];R6-$W*.3GGP*5P "RA&T2@X)3\-FJDM>70DV%)5!
MX:F %0>1V5,0%B"SKRO&MJYP'^(26EN0SD1IRT2&9# Q#EHTL!BXG.*9IN<Z
M-]EM)%"<9@B>"/D/HLN(B 8*Y.QAH&CG+8+WXS?\(B54$<,,BDZ>X:9PGW'$
MGQ[*IW83&>' Y1SST-=\-1T2WH1RVP+&[49(9S#@\RYLGV%4(*0_[-@?UL'G
MW""?E+X0^JA_E;[V"><''F,U\IE*N,!*CH7<C<A_&=2/EAFB/JG#ZW+9)P,U
M@&QRXKQ$5)-ND7;406>8?0%8KI_;^X=S.,46Q>-N4H,]IS W"*:UFPY1L2G6
M4'?"F2,/25K&0AGY]$G20P3M!K:TRA,8E\82#PI6GB UN3&APRWL4N98#,.U
M*RH5G#V8QC"(QX5:>K!RTCRF]05;AS"S!_Y!)D6:@-UCI)U1FBGX EG'H?Z2
M@?#96B=65^'&U0]54!+(?F+'TLKQ<)C5R8'CI!P5*3$?'5%S[?WE$A+4C.O*
MQJJJD^DAD-:0Z)F0H2_+A%DB8O@6OE(FBLQPJ""X[9M4F"*TV:B0U:?V;G[D
M&6*D6L\4A%6\60!4W2=GR2 V5".7:6G! @G]!7,3A0+=F4T8 U?]Q=311H38
M^UZ B?%4(G[M$M?:2E0R]HN"J:#=#ROW>(Q "%>C7K;BM9;' &LIL/87)N\E
M1 3X>.-5ZWEH$ZVX\VW?;DVUDJ7.+G&XJTKSRC*7KC'^#VF  1F<B"9,>@CQ
MA1G2AA"&Z4]^,?U-/,7.P"'FQZ8L)D>?P5!?1D.+&\9P!0O0ALR>D#W17<1
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M.Y)@9Q)@\C=S^#;N<KE;QT&N?LGT=4F$%KN**D,99\3T$]7N%WBODVNI9%7
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M6V>+9*)18!W6^Z=,Q\ZXNXT5S&)K1_4&.L=@IE.2M_G,9KZ6T,_;Q\_3X[L
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M\]DWJ-_("V^,Y>8A*-\&C/3]*94.!<\+8K_!XK<UFC^I-LIE\B\R1D^]E#3
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M<DNOI)-WBNR5WMT6-\C66F*7VGFA6W#57F&[:?ZP9V-C9"4T1LH0@\[B'RQ
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MZ$(!!E,"JMF&>0!T5%^_"F*XCLMXOH]*&FE\8P1PC.PBB$B,TMS?+'.>,OE
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MK ]Y0;EX;_-->W^[V][<V]TN[RS9?QXK;4&1;L[_@4'^QLQ_ 5!+ 0(4 Q0
M   (  = ZEK;>NOP0 ,  $\+   1              "  0    !C;V=T+3(P
M,C4P-S W+GAS9%!+ 0(4 Q0    (  = ZEI0WE2W>P8  +E&   5
M      "  6\#  !C;V=T+3(P,C4P-S W7VQA8BYX;6Q02P$"% ,4    "  '
M0.I:1Z>!<\($  !!+   %0              @ $="@  8V]G="TR,#(U,#<P
M-U]P<F4N>&UL4$L! A0#%     @ !T#J6@S7Z.#/%   37X   T
M     ( !$@\  &0Y,C@P.&0X:RYH=&U02P$"% ,4    "  '0.I:MG/8KYJ+
M  !3NP( #P              @ $,)   9#DR.# X9&5X,3$N:'1M4$L! A0#
M%     @ !T#J6F_.A6!."   B!X   \              ( !TZ\  &0Y,C@P
M.&1E>#4Q+FAT;5!+ 0(4 Q0    (  = ZEJ>YL?G0A<  #A3   0
M      "  4ZX  !D.3(X,#AD97@Y.3$N:'1M4$L%!@     '  < N $  +[/
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d92808d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cogt-20250707.xsd" xlink:type="simple"/>
    <context id="duration_2025-07-07_to_2025-07-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001622229</identifier>
        </entity>
        <period>
            <startDate>2025-07-07</startDate>
            <endDate>2025-07-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-307">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-07-07_to_2025-07-07"
      id="Hidden_dei_EntityCentralIndexKey">0001622229</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-318">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-319">2025-07-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-320">COGENT BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-321">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-322">001-38443</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-323">46-5308248</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-324">275 Wyman Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-325">3rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-326">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-327">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-328">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-329">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-330">945-5576</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-331">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-332">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-333">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-334">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-335">Common stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-336">COGT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-337">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-07-07_to_2025-07-07" id="ixv-338">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
